SCHEMBL25822705

SCHEMBL25822705

Nc1ccc(Br)cc1-n1ccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.66
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
CYP11B1 P15538 4/20 0.42
CYP17A1 P05093 1/20 0.42
CYP21A2 P08686 1/20 0.42
CYP3A4 P08684 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP19A1 P11511 3/20 0.39
CYP11B2 P19099 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1239654 0.86 IDO1 (0.53) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL19036228 0.84 IDO1 (0.46) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL13242920 0.79 IDO1 (0.66) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL7970075 0.79 IDO1 (0.66) IDO1LMNAMAPTCYP11B1CYP3A4
SCHEMBL2657862 0.79 IDO1 (0.45) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL27776126 0.77 IDO1 (0.62) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL8283425 0.76 CYP3A4 (0.44) IDO1LMNAMAPTCYP11B1CYP17A1
SCHEMBL4829700 0.76 IDO1 (0.61) IDO1LMNAMAPTCYP11B1CYP3A4
SCHEMBL30963680 0.76 KDM4E (0.54) IDO1LMNAMAPTCYP3A4CYP1A2
SCHEMBL25025011 0.76 IDO1 (0.60) IDO1LMNAMAPTCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 IDO1 1184/4885LMNA 4857/4885MAPT 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.